Reports Summarize Cancer Gene Therapy Findings from Bristol-Myers Squibb Company (Challenges and Lessons Learned In Autologous Chimeric Antigen Receptor T-cell Therapy Development From a Statistical Perspective).

A recent study conducted by Bristol-Myers Squibb Company explores the challenges and lessons learned in the development of autologous chimeric antigen receptor (CAR) T-cell therapy from a statistical perspective. CAR T-cell therapy is a form of gene therapy where a patient's T cells are genetically modified to better recognize target antigens. Despite the progress made in CAR T-cell therapies, there are still statistical challenges that need to be addressed, such as dose finding strategies, the use of real-world data, and long-term safety analysis. This research aims to summarize and address these statistical hurdles based on the development of the six approved CAR T-cell products. [Extracted from the article]